0000000000355140

AUTHOR

Gaetano Scotto

showing 4 related works from this author

Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial

2008

It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n_696) received peginterferon alfa-2a, 180 mg/week, or peginterferon alfa-2b, 1.5 mg/kg/week, plus ribavirin, 1000-1200 mg/day, for 48 weeks (standard, n _237) or for 24, 48, or 72 weeks if HCV-RNA–negative at weeks 4, 8, or 12, respectively (variable, n _ 459). Sustained virologic response (SVR) was achieved in 45.1% [95% confidence interval (CI) 38.8-51.4] of the patients in the standard group and in 48.8% (CI 44.2-53.3) of the patients in the variable group (P _ 0.37). The percentages of …

AdultMalemedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineRibavirinmedicineHumansProspective StudiesRapid Virologic Responsegenotype 1Hepatologybusiness.industryRibavirinStandard treatmentInterferon-alphavirus diseasesHepatitis CMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesConfidence intervalSurgeryTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalehepatitis Cbusiness
researchProduct

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.

2010

The benefit of individualizing treatment for patients with genotype 3 HCV infection on the basis of viral clearance at week 4 (wk4-R) has not been firmly established.Four hundred and fourteen patients received Peg-interferon alpha-2b plus 1000-1200 mg of ribavirin daily according with body weightor75 kg. Patients were randomized to standard 24 weeks (Std24) or to a 12 or 36 weeks variable treatment duration (Var12/36). In the variable treatment arm, patients with or without wk4-R were allocated to either 12 or 36 weeks duration.At treatment week 4, HCV RNA was undetectable in 262 patients (63.3%), 136 in the Std24, and 126 in the Var12/36 group (p=0.41). In patients with wk4-R, end-of-treat…

AdultMalemedicine.medical_specialtyAdolescentGenotypeAlpha (ethology)Alpha interferonHepacivirusInterferon alpha-2GastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundYoung AdultPharmacotherapyInternal medicineGenotypeRibavirinmedicineHumansIn patientPrecision MedicineAgedHepatologybusiness.industryStomachRibavirinInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsSurgerymedicine.anatomical_structurechemistryRNA ViralFemalebusinessJournal of hepatology
researchProduct

HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years

2012

Background & Aims In long-term responder patients, it is unclear whether lamivudine (LAM) monotherapy should be continued or switched to a high-genetic-barrier analogue. This study aims at assessing LAM efficacy over a 5-year period and the residual risk of drug resistance. The rate of HBsAg clearance and LAM long-term safety profile were also evaluated. Methods One hundred and ninety-one patients with chronic HBeAg-negative hepatitis B successfully treated with LAM monotherapy for at least 5years were included. Biochemical and virological tests were assessed every 3months in all patients and HBsAg quantification was performed in 45/191. Reverse-transcriptase (RT) region was directly sequen…

AdultMaleHBsAgmedicine.medical_specialtyChronic hepatitis B; Lamivudine; Nucleos(t)ide analogues; Viral resistance; Adult; Aged; Antiviral Agents; DNA Viral; Female; Hepatitis B Surface Antigens; Hepatitis B e Antigens; Hepatitis B Chronic; Humans; Lamivudine; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Time Factors; HepatologyTime FactorsCirrhosisDrug resistanceReal-Time Polymerase Chain Reactionmedicine.disease_causeChronic hepatitis BAntiviral AgentsGastroenterologyHepatitis B ChronicInternal medicineHBVmedicineHumansViralHepatitis B e AntigensChronicAgedHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryViral resistanceLamivudineDNAMiddle AgedHepatitis BHepatitis Bmedicine.diseaseNucleos(t)ide analoguesResidual riskHBeAgLamivudineDNA ViralImmunologyFemalebusinessmedicine.drug
researchProduct

Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug us…

2011

Abstract The global spread of hepatitis B virus (HBV) and hepatitis C virus (HCV), their high chronicity rates and their progression to cirrhosis and hepatocellular carcinoma, are major public health problems. Research and intervention programmes for special population groups are needed in order to assess their infection risk and set up suitable prevention and control strategies. Aim of this paper is to give health care professionals information on HBV and HCV infections amongst migrants, drug users and prison inmates. The manuscript is an official Position Paper on behalf of the following Scientific Societies: Italian Association for the Study of the Liver (A.I.S.F.), Italian Society of In…

medicine.medical_specialtymedia_common.quotation_subjectHCV HBV vaccimantion inmatesPopulationPsychological interventionPrisonContext (language use)migrantsmedicine.disease_causeVulnerable PopulationsDrug UsersHepatitis B ChronicHealth carehcvMedicineHumanseducationPsychiatrySubstance Abuse Intravenousmedia_commonHepatitis B virusTransients and Migrantseducation.field_of_studyHepatologybusiness.industryPublic healthPrisonersVaccinationGastroenterologyvirus diseasesHepatitis C Chronicintravenous drug usersSocioeconomic FactorsPractice Guidelines as TopichbvPosition paperhbv; hcv; intravenous drug users; migrants; prison inmatesbusinessprison inmates
researchProduct